Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M. Patnaik, David A. Sallman, Abhishek A. Mangaonkar, Rachel Heuer, Jeffery Hirvela, Darci Zblewski, Aref Al‐Kali, Moritz Binder, Maria E. Balasis, Hannah Newman, Christopher T. Letson, Traci Kruer, Naseema Gangat, Rami S. Komrokji, Ayalew Tefferi, Adrian Lo, Ted Shih, Cameron Durrant, Alan F. List, Eric Padron
Abstract
In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) was associated with clinically meaningful responses in 5 of 15 patients with relapsed or refractory chronic myelomonocytic leukemia (CMML). Preliminary data suggest that this approach may be tractable in CMML bearing activating NRAS mutations.
Topics & Concepts
Chronic myelomonocytic leukemiaGranulocyte macrophage colony-stimulating factorMedicineImmunologyRecombinant DNAAntibodyNeuroblastoma RAS viral oncogene homologLeukemiaCancer researchInternal medicineBiologyCancerCytokineGeneBone marrowMyelodysplastic syndromesGeneticsKRASColorectal cancerAcute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia ResearchImmune Cell Function and Interaction